The USPTO issued patent US12595312B2 granting the University of Toronto exclusive rights to CD133-binding agents and their uses in cancer detection, targeting, and treatment. The patent specifically covers methods for detecting CD133-expressing cells, quantitating CD133 expression levels, targeting such cells, decreasing cellular CD133 levels, and treating or preventing cancer using the disclosed binding agents.

For pharmaceutical and biotechnology companies engaged in cancer research or development of cell surface marker targeting technologies, this patent establishes intellectual property barriers around CD133-binding compositions and their diagnostic/therapeutic applications. Entities developing similar binding agents, diagnostics, or treatments involving CD133-expressing cells should conduct freedom-to-operate analyses and consider potential licensing arrangements with the University of Toronto to avoid infringement risk.